Paragon Advisors’s ResMed RMD Stock Holding History

Paragon Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,968	Closed	-$1.33M	–	124
2023 Q3	$1.33M	Buy	+8,968	New	+$1.62M	0.55%	42

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Paragon Advisors's RMD Position: Q4 2023 in Review

Paragon Advisors sold out of ResMed (RMD) in Q4 2023, closing a stake of 8,968 shares — an estimated $1.33M sold.

Paragon Advisors first reported a position in RMD in Q3 2023 and held it in 1 quarter. The position peaked at $1.33M in Q3 2023. 688 funds tracked by Wall St. Rank hold RMD as of Q4 2023.

Paragon Advisors reported no remaining ResMed position as of Q4 2023 after selling out during the quarter.
Paragon Advisors sold 8,968 ResMed shares in Q4 2023, an estimated $1.33M.
Paragon Advisors first reported a position in ResMed in Q3 2023 and held it in 1 quarter.
Paragon Advisors's ResMed position peaked at $1.33M in Q3 2023.
688 funds tracked by Wall St. Rank held ResMed as of Q4 2023.

Based on Paragon Advisors's 13F filing for Q4 2023, filed 6 Feb 2024.